Cohance Lifesciences Names Former Intas Executive Abhimanyu Ojha as New CFO

The decision was approved by the Board of Directors of the company during its meeting held on Friday, October 9, 2026, following the unanimous recommendation of its Nomination and Remuneration Committee. The company confirmed that there is no fixed term for the appointment and that there are no inter-se relationships between Abhimanyu Ojha and any of the existing directors on the company's Board.

Abhimanyu Ojha brings over two decades of extensive executive leadership experience managing finance functions across global healthcare and pharmaceutical organizations. Prior to joining Cohance Lifesciences Limited, he served as the Global Chief Financial Officer and President of Finance at Intas Pharmaceuticals. In that role, he directed global finance operations encompassing business operations, manufacturing, research and development (R&D), accounting, treasury, internal audit, taxation, corporate finance, as well as financial planning and analysis (FP&A).

Earlier in his career, Ojha held multiple senior leadership positions at Viatris (formerly Mylan), Sun Pharmaceuticals, and Ranbaxy Laboratories, collaborating closely with functional and commercial leaders across diverse international geographies. Throughout his career, he has played a pivotal role in driving strategic business growth, bolstering financial performance, and steering global organizational transformations. His expertise spans financial strategy, business partnering, corporate governance, mergers and acquisitions (M&A), treasury management, taxation, risk mitigation, and operational excellence. He has built global finance teams and partnered closely with Chief Executive Officers, executive committees, boards of directors, investors, and business leaders, employing a leadership style that balances empowerment with accountability to foster decision-making, ownership, and performance delivery.

Consequent to the CFO appointment, the Board of Directors also approved updates to the authorized Key Managerial Personnel designated to determine the materiality of an event or information and make required stock exchange disclosures under Regulation 30(5) of the SEBI Listing Regulations. The company's “Policy for Determining Material Event or Information” has been formally amended to reflect these changes, taking effect on October 12, 2026.

The three authorized Key Managerial Personnel designated for determining materiality and handling disclosures under the amended policy are: Umang Vohra, Chairman & Group CEO; Abhimanyu Ojha, Chief Financial Officer; Sisir K. Mishra, Company Secretary & Compliance Officer.